The article focuses on the use of anticancer drugs in treating protein KRAS-driven cancer. Topics discussed include the use of checkpoint kinase 1 (CHK1) control initiation and kinase-activated protein kinase 2 (MK2) in cancer treatment, the effects of CHK1 and MK2 inhibitors in human cancer cells, and the effectivity of combined checkpoint kinase inhibition.